Comparative Study of PD-L1 Expression in Different Sites of Non-small Cell Lung Cancer
Background and objective The expression of programmed cell death ligand 1 (PD-L1) as a biomarker for immunotherapy in non-small cell lung cancer (NSCLC) is routinely detected in clinical pathology department. However, the spatial heterogeneity of PD-L1 expression in intrapulmonary tumors and extrapu...
Main Authors: | Xiaozheng HUANG, Jianghua WU, Lixin ZHOU, Zhijie SONG, Wantong XU, Ling JIA, Xinting DIAO, Qi WU, Dongmei LIN |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2022-05-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.14 |
Similar Items
-
Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer
by: Yan SHI, et al.
Published: (2017-11-01) -
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01) -
Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
by: Sue Youn Kim, et al.
Published: (2022-06-01) -
Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for
Non-small Cell Lung Cancer
by: Cheng LIN, et al.
Published: (2014-10-01) -
Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1
by: Takuma Katano, et al.
Published: (2020-01-01)